Govt Approves 1st Use Of Regenerative Medicine In Japan (Japan)
This article was originally published in PharmAsia News
The Japanese government has given approval to Bioventure Japan Tissue Engineering Co. (J-TEC) to manufacture and sell skin for use in treating serious burns, the first such approval for the use of regenerative medicine in Japan. Skin cells that have been cultured for approximately two weeks are used in the treatment, with technology enabling a 1-sq.-cm sample to grow up to 1,000 times larger. The new skin, once grown, is applied to the damaged part of the body, significantly reducing the chances of rejection compared with procedures using another person's skin. J-TEC also plans to seek approval from the Health Ministry for regenerative treatments to restore the functions of knee cartilage and the epithelium of the cornea. (Click here for more - May Require Paid Subscription
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.